HHS lowers monetary penalties for HIPAA violations

HHS has changed its regulations for civil monetary penalties (CMP) under the Health Insurance Portability and Accountability ACT of 1996 (HIPAA), effectively lowering penalties across four categories of violations.

Instead of an annual upper limit of $1.5 million, the CMP limit is lowered to $25,000 when the affected party had "no knowledge" in a violation under the changes. 

The change enforces different CMP limits across the four penalty tiers outlined in the Health Information Technology for Economic and Clinical Health (HITECH) Act. Current regulations maintain the same CMP limit for all penalties. 

The $1.5 million cap remains in place for HIPAA violations with "will neglect–not corrected," while the cap for parties with violations of "reasonable cause" is lowered to $100,000 annually and the "will neglect–corrected" cap is lowered to $250,000.

HHS plans to use the new penalty tier structure going forward, with adjustments for inflation, according to the agency.

HIPAA violations that expose patient data can be costly incidences for healthcare providers for a variety of reasons. Last year, three hospitals in Boston paid nearly $1 million to settle HIPAA violation accusations over the filming of a television documentary series without receiving patient authorization.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.